Abstract: Labels that include dibromopyridazinedione attached to signal molecules are disclosed, along with methods of producing and using same. Also disclosed are conjugates of the label attached to an analyte-specific binder, as well as methods of producing and using same. Kits containing the labels and/or conjugates are also disclosed, along with microfluidics devices containing same.

Abstract: Anti-hog TCN1 monoclonal antibodies are disclosed, along with epitopes recognized by same. Also disclosed are kits containing the monoclonal antibodies and methods of producing the antibodies. Further disclosed are methods of using the monoclonal antibodies, such as (but not limited to) in methods of estimating and/or removing TCN1 from hog intrinsic factor preparations.

Abstract: Antibodies that specifically bind naloxone or naltrexone are disclosed. Also disclosed are conjugates used in the production of the antibodies, as well as methods of producing the antibodies. Also disclosed are methods of using the antibodies in direct assays for naloxone or naltrexone. Further disclosed are methods of reducing naloxone or naltrexone interference in opiate assays using the antibodies.

Abstract: The invention relates to a method of detecting nucleic acid molecules by immunoassay detection. Detection of a specific nucleic acid molecule of interest is achieved by using a nucleic acid probe in solution which hybridizes in solution to the nucleic acid molecule of interest. Immunoassay detection is achieved by using an antibody specific for the hybrid formed by hybridization of the nucleic acid probe to the nucleic acid molecule of interest.

Abstract: Methods include adjusting a contribution of one of two analyte homologs to an amount of signal obtained in an assay for determining a total amount of the two analyte homologs in a sample. A non-assay receptor is employed that has a greater binding affinity for whichever of the two analyte homologs whose contribution to the amount of signal is to be adjusted. An amount of the non-assay receptor is sufficient to achieve an adjustment of the contribution of the analyte homolog to the signal. The assay for determining the total amount of the two analyte homologs is conducted where the assay utilizes at least one assay antibody.

Abstract: The present invention relates to immobilized procainamide analogs, as well as to a method of making immobilized procainamide analogs. These immobilized analogs are prepared by activating the carboxyl group on a substituted p-benzoic acid derivative toward nucleophilic attack; reacting the activated benzoic acid derivative with a polyamine to produce the benzoic acid derivative of Formula 3: and binding the benzoic acid derivative of Formula 3 to a latex polymer having functional groups that react with aliphatic amino groups. A method of conducting an immunoassay using the immobilized procainamide analog Formula 3 is described, comprising the steps of preparing a solution comprising said immobilized procainamide analog; adding a sample suspected of containing procainamide to said solution; adding an anti-procainamide antibody to said solution and observing the rate of increase in solution turbidity following antibody addition.

Abstract: The present invention relates to immobilized procainamide analogs, as well as to a method of making immobilized procainamide analogs. These immobilized analogs are prepared by activating the carboxyl group on a substituted p-benzoic acid derivative toward nucleophilic attack; reacting the activated benzoic acid derivative with a polyamine to produce the benzoic acid derivative of Formula 3: and binding the benzoic acid derivative of Formula 3 to a latex polymer having functional groups that react with aliphatic amino groups. A method of conducting an immunoassay using the immobilized procainamide analog Formula 3 is described, comprising the steps of preparing a solution comprising said immobilized procainamide analog; adding a sample suspected of containing procainamide to said solution; adding an anti-procainamide antibody to said solution and observing the rate of increase in solution turbidity following antibody addition.